Scholze et al. BMC Public Health 2010, 10:529 http://www.biomedcentral.com/1471-2458/10/529 and low-density lipoprotein cholesterol control and accuracy of diagnosis. J Cardiometab Syndr 2007, 2:9-15. 18. de la SA, Romero R, Bonet J, Perez M, Lopez JS, Ravella R, et al: [Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population]. Med Clin (Barc) 2006, 126:406-409. 19. Assmann G, Guerra R, Fox G, Cullen P, Schulte H, Willett D, et al: Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol 2007, 99:541-548. 20. Cordero A, Laclaustra M, Leon M, Grima A, Casasnovas JA, Luengo E, et al: Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens 2006, 19:189-196. 21. Ferrara LA, Cardoni O, Mancini M, Zanchetti A: Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J Hum Hypertens 2007, 21:795-801. 22. Mancia G, Parati G, Borghi C, Ghironzi G, Andriani E, Marinelli L, et al: Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens 2006, 24:837-843. 23. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al: Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007, 49:40-47. 24. Romero R, Bonet J, de la SA, Aguilera MT, Esopoh SI: Undiagnosed obesity in hypertension: clinical and therapeutic implications. Blood Press 2007, 16:347-353. 25. Navarro J, Redon J, Cea-Calvo L, Lozano JV, Fernandez-Perez C, Bonet A, et al: Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC-HTA study. Blood Press 2007, 16:20-27. 26. de la SA, Romero R, Bonet J, Perez M, Lopez JS, Ravella R, et al: [Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population]. Med Clin (Barc) 2006, 126:406-409. 27. Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C: Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008, 26:2064-2070. 28. Wille E, Scholze J, Alegria E, Ferri C, Langham S, Stevens W, et al: Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ 2010. 29. Expert Panel on Detection EaToHBCiA: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. 30. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572. 31. Robert Koch Institute: Public Use File BGS98, German National Health Interview and Examination Survey 1998. Berlin (Germany), Robert Koch Institute 2000. 32. Perez-Fernandez R, Marino AF, Cadarso-Suarez C, Botana MA, Tome MA, Solache I, et al: Prevalence, awareness, treatment and control of hypertension in Galicia (Spain) and association with related diseases. J Hum Hypertens 2007, 21:366-373. 33. Mancia G, Volpe R, Boros S, Ilardi M, Giannattasio C: Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care. J Hypertens 2004, 22:51-57. 34. Datamonitor: Stakeholder Insight: Metabolic Syndrome. Delaney, A, Fleetwood, and A. New York., Datamonitor 2004. 35. Gandjour A, Stock S: A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost- effectiveness. Health Policy 2007, 83:257-267. 36. Rovira J, Badia X, Pardell H: Cost of hypertension in Spain. J Hum Hypertens 1992, 6:481-483. Page 11 of 12 37. Degli EE, Berto P, Ruffo P, Buda S, Degli EL, Sturani A: The PANDORA project: results of the cost of illness analysis. J Hum Hypertens 2001, 15:329-334. 38. Esposti LD, Di Martino M, Saragoni S, Sgreccia A, Capone A, Buda S, et al: Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens (Greenwich) 2004, 6:76-84. 39. Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, % 20(369):201-207. 40. Hansson L, Lloyd A, Anderson P, Kopp Z: Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press 2002, 11:35-45. 41. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, et al: The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008, 24:121-127. 42. Noto D, Barbagallo CM, Cefalu AB, Falletta A, Sapienza M, Cavera G, et al: The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 2008, 197:147-153. 43. Mar J, Rodriguez-Artalejo F: Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens 2001, 19:149-155. 44. Taylor MJ, Scuffham PA, McCollam PL, Newby DE: Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr Med Res Opin 2007, 23:495-503. 45. Mullins CD, Sikirica M, Seneviratne V, Ahn J, Akhras KS: Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 2004, 22:1001-1014. 46. Jonsson B: Revealing the cost of Type II diabetes in Europe. Diabetologia 2002, 45:S5-12. 47. International Association for the Study of Obesity: Adult overwieght and obesity in EU 27. 2009 [http://www.iotf.org/database/documents/ AdultEU27March2010notonwebyetupdatev2.pdf]. 48. Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN: Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008, 8(200), schemas-com. 49. Neuhauser H, Ellert U: Estimation of the metabolic syndrome prevalence in the general population in Germany. J Public Health 2008, 16:221-227. 50. de la SA, Romero R, Bonet J, Perez M, Lopez JS, Ravella R, et al: [Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population]. Med Clin (Barc) 2006, 126:406-409. 51. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C: The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004, 63:395-401. 52. Kiiskinen U, Vartiainen E, Puska P, Aromaa A: Long-term cost and life- expectancy consequences of hypertension. J Hypertens 1998, 16:1103-1112. 53. de la SA, Romero R, Bonet J, Perez M, Lopez JS, Ravella R, et al: [Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population]. Med Clin (Barc) 2006, 126:406-409. 54. National Institute for Health and Clinical Excellence: CG34: Hypertension: NICE clinical guidelines. London, UK, National Institute for Health and Clinical Excellence 2006. 55. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009, 18:308-347. 56. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al: Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008, 26:819-824. 57. Mathes J, Kostev K, Gabriel A, Pirk O, Schmieder RE: Risks and costs of the first hypertension-associated event, compliance and persistence in niave hypertensive patients after initiating monotherapy. Value Health 2008, 11. 58. Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.